Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, today announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed... read more
Atlas Venture, a leading venture capital firm investing in breakthrough biotech innovation, today announced the closing of its first Opportunity Fund, raising $250 million in an oversubscribed... read more
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating Xtandi (enzalutamide)... read more
On 12/20/18, Relay Therapeutics announced the successful completion of a $400 million Series C financing.
Relay Therapeutics combines unprecedented computational power with leading... read more
Equillium, Inc. (Nasdaq: EQ) announced on 12/19/18 that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EQ001 for the treatment of acute graft-versus-host... read more
Auron Therapeutics and Elucidata Corporation on 12/19/18 announced a scientific collaboration using Elucidata’s AI-based target discovery platform to identify and validate targets for... read more